saturday morning dr kenneth fischbeck national institutes health guest kda chat room dr fischbeck leading researcher professor educator subject kennedy disease chat focused two current nih research projects finding treatment kennedy disease excerpts chat entire chat found kda website starting nih trial drug novartis trial compound called bvs novartris development activates igf pathway fits studies group nih shown benefit igf mouse versions kd pretty exciting get stage result several years work mice lab year half working folks novartis bvs trial also include several sites europe italy germany denmark bvs version igf work muscles also help protect motor neurons igf expect bvs helps stimulate muscle growth also help increasing breakdown mutant androgen receptor protein bvs new drug yet approved fda starting kd patients area make sure safe first due get first dose tuesday recruiting july goes well another next january trial parts part tests increasing doses safety tolerability part tests highest tolerated dose efficacy week period idea bvs would given injection like insulin planning weekly injections best guess present see long drug stays bloodstream trial may wind giving less often weekly works part patients get injections gradually increasing doses every weeks currently plan give injections week part randomize part patients drug placebo placebo needed comparison test whether drug really working part patients involve weeks treatment hope see benefit months time frame finish part starting end year part end possible side effects low blood sugar like insulin high doses also igf bvs high doses caused facial weakness bell palsy two things trying careful keeping doses low advancing slowly also giving drug people low igf begin kd patients low igf part using thigh muscle mri way confirm drug increasing muscle growth also testing muscle strength function patients fill questionnaires see strong feel bvs study taking patients weakness still able walk least minutes without cane decided test bvs first range patients weak still able walk hope would also help patients weaker perhaps yet muscle weakness slow prevent onset hope bvs also help patients wheelchair bound see whether works patients able walk first safety reasons patients come nih weekly injections follow cover travel expenses see eligible contact angela kokkinis nih akokkinis nih gov telephone selected first two subjects bvs trial plenty opportunity patients join later year next able get nih one european sites weekly basis live outside best bet contact one sites europe coming online next months interested participating currently taking avodart dutasteride rules trial require patients androgens anti androgens dutasteride least months starting inclusion exclusion criteria listed clinicaltrials gov website ask angela current trial successful would probably follow studies places small chance fda would approve drug strong effect study usually like least two positive studies approval trial posted publically clinicaltrials gov website search bvs kennedy disease nih clinical center website company yet made public details drugs composition pending patent application reference trials laura bott cartlo rinaldi lab working asc jm asc mice interesting results able confirm drugs benefit mice although strong effect reported previously working mechanism action help developing potent drug